These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions. Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129 [TBL] [Abstract][Full Text] [Related]
9. Enzyme kinetics of cytochrome P450-mediated reactions. Shou M; Lin Y; Lu P; Tang C; Mei Q; Cui D; Tang W; Ngui JS; Lin CC; Singh R; Wong BK; Yergey JA; Lin JH; Pearson PG; Baillie TA; Rodrigues AD; Rushmore TH Curr Drug Metab; 2001 Mar; 2(1):17-36. PubMed ID: 11465149 [TBL] [Abstract][Full Text] [Related]
11. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Houston JB; Kenworthy KE Drug Metab Dispos; 2000 Mar; 28(3):246-54. PubMed ID: 10681367 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro - in vivo extrapolation of hepatic clearance. Palacharla RC; Uthukam V; Manoharan A; Ponnamaneni RK; Padala NP; Boggavarapu RK; Bhyrapuneni G; Ajjala DR; Nirogi R Eur J Pharm Sci; 2017 Apr; 101():80-89. PubMed ID: 28179134 [TBL] [Abstract][Full Text] [Related]
14. [Research progress of the atypical kinetic profiles of cytochrome P450 enzymes]. Zeng CW; He F; Xia CH; Xiong YQ Yao Xue Xue Bao; 2012 Jun; 47(6):725-9. PubMed ID: 22919718 [TBL] [Abstract][Full Text] [Related]
15. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. Yadav J; Paragas E; Korzekwa K; Nagar S Pharmacol Ther; 2020 Feb; 206():107449. PubMed ID: 31836452 [TBL] [Abstract][Full Text] [Related]
16. Modeling kinetic data from in vitro drug metabolism enzyme experiments. Tracy TS; Hummel MA Drug Metab Rev; 2004 May; 36(2):231-42. PubMed ID: 15237853 [TBL] [Abstract][Full Text] [Related]
17. Heterotropic cooperativity in oxidation mediated by cytochrome p450. Niwa T; Murayama N; Yamazaki H Curr Drug Metab; 2008 Jun; 9(5):453-62. PubMed ID: 18537580 [TBL] [Abstract][Full Text] [Related]
18. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits. Rendic SP; Peter Guengerich F Drug Metab Rev; 2018 Aug; 50(3):256-342. PubMed ID: 30717606 [TBL] [Abstract][Full Text] [Related]
19. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Lin Y; Lu P; Tang C; Mei Q; Sandig G; Rodrigues AD; Rushmore TH; Shou M Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):368-74. PubMed ID: 11259318 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib. Wang Z; Yong Chan EC Drug Metab Dispos; 2022 Oct; 50(10):1332-1341. PubMed ID: 35817438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]